Syra Health Corp. (SYRA) intrinsic value & 10-year financials
Syra Health Corp. (SYRA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue grew 8.8% a year to $7.2M, with an average return on invested capital of -336.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.84
- Market cap
- $10.0M
- Revenue (FY2025)
- $7.2M
- Revenue growth (5-yr CAGR)
- 8.8%
- ROIC (10-yr avg)
- -336.7%
- Free cash flow (FY2025)
- -$447.9K
SYRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.2M | -$896.3K | -$0.08 | -$447.9K | -12.5% | -134.9% |
| FY2024 | $8.0M | -$3.8M | -$0.50 | -$2.9M | -47.2% | -561.6% |
| FY2023 | $5.5M | -$2.9M | -$0.60 | -$2.8M | -52.4% | -375.0% |
| FY2022 | $5.6M | -$2.1M | -$0.70 | -$2.4M | -37.2% | -275.1% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Syra Health Corp revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Syra Health Corp has historically struggled to out-earn its cost of capital, averaging just -36.8% ROIC.
Syra Health Corp capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Syra Health Corp is modeled at 8.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.69 per share.